BRSE yields 666666.67% · ABBV yields 3.06%● Live data
📍 BRSE pulled ahead of the other in Year 1
Combined, BRSE + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BRSE + ABBV for your $10,000?
Broadside Enterprises, Inc. operates in media, branded goods, real estate, and blockchain technologies businesses. Its Media division focuses on the development, financing, acquisition, and distribution of media assets. The company's Branded Goods division focuses on discovering and building brands with stellar potential. This division utilizes information technology, as well as its media expertise to connect brands directly to consumers. Its Real Estate division seeks to finance, acquire, and develop long-term assets in residential and commercial real estate, as well as natural resources with focus on Africa and the Middle East. The company's Blockchain Technologies division focuses on crypto-mining operation, as well as developing token and blockchain applications for the media, branded goods, and real estate industries. Broadside Enterprises, Inc. was formerly known as Emaji, Inc. and changed its name to Broadside Enterprises, Inc. in December 2016. The company was incorporated in 1996 and is based in West Hollywood, California.
Full BRSE Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.